Review
S Afr Med J 2014;104(3):174-177. DOI: 10.7196/SAMJ.7968
This interim guidance is aimed at assisting organizers of international meetings attended by individuals from EVD-affected countries and individuals with a travel history to EVD-affected countries within the previous 3 weeks.
The first part is intended for organizers of international meetings, to ...safely plan and conduct these events. The second part is addressed to public health authorities directly involved in supporting such international meetings.
more
Journal des anthropologues n° 138-139, 2014
http://journals.openedition.org/jda/4444
Le médicament pharmaceutique industriel est un objet de santé
à la fois scientifique, populaire et marchand. Si ces deux premiers
caractères sont souvent mis en avant respectivement par les sciences
biom...édicales et pharmaceutiques, par la santé publique ainsi qu’à
travers les médias, sa troisième composante est plus souvent passée
sous silence. Elle tend à être dissimulée derrière ce qui est présenté
comme la vocation première du médicament, à savoir la santé des
individus, leur bien-être physique et psychique. Or, le caractère
marchand du médicament est un formidable vecteur de dynamiques
et d’initiatives. Il est peut-être ce qui explique avant tout
l’incroyable vitalité du secteur pharmaceutique de par la planète,
non sans poser de nombreux problèmes d’ordre sanitaire et de santé
publique.
more
This document builds on the Background document prepared for the September 4-5, 2014 Consultation. It includes proposed elements to consider during the development of a framework to assist decision-making at global and national level.
The aim of the document is to assist Member States and releva...nt partners in their discussions to identify the best approaches to ensure the accelerated evaluation and use of available or near-term therapies and vaccines for the treatment and prevention of EVD. The document calls for a coordinated effort by the international community to remove unnecessary obstacles towards this goal.
more
Good practice examples from India
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
Findings on maternal and child health in Nepal, Mozambique and
Rwanda, and neglected tropical diseases in Cambodia and Sierra Leone | This report synthesises findings from five country case studies from the health dimension of this project, which focus on maternal and child health (MCH) (Mozambique...,Nepal, Rwanda) and neglected tropical diseases (NTDs)(Cambodia, Sierra Leone). MCH was selected given its centrality in two of the Millennium Development Goals (MDGs) and its ability to act as a proxy for strengthened health systems. NTDs, while until recently relatively neglected in global policy debates, are now attracting more interest, not least because they are viewed as diseases of the poor whose treatment could positively impact on most of the other MDGs.
more
Version 1.0, 2014-11-21
Introduction:
This document lists TB indicators that can be derived from the recording and reporting tools defined
in Definitions and reporting framework for tuberculosis – 2013 revision (WHO/HTM/TB/2013.2).
Geneva, World Health Organization; 2013. (http://www.who.int/t...b/publications/definitions/en/).
More details on the rationale, calculation and use of these indicators are available in the following
publications:
• Understanding and using tuberculosis data (WHO/HTM/TB/2014.09). Geneva, World Health
Organization. 2014.
(http://www.who.int/tb/publications/understanding_and_using_tb_data/en/)
• Companion handbook to the WHO guidelines for the programmatic management of drugresistant
tuberculosis (WHO/HTM/TB/2014.11). Geneva, World Health Organization. 2014.
(http://www.who.int/tb/publications/pmdt_companionhandbook/en/)
• A guide to monitoring and evaluation for collaborative TB/HIV activities: 2014 revision. Geneva,
World Health Organization. 2014.
more